At the 2024 annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Vancouver, Canada, Hélio Tomás, PhD, senior research associate at the Instituto de Biologia Experimental e ...
TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...
A novel approach to automating cell therapy manufacturing using industry-standard equipment can potentially reduce human errors, deliver higher quality product, and lower manufacturing costs by ...
Tevogen Bio announced an agreement with CD 8 Technology Services to develop a turn-key facility aimed at enhancing its in-house capabilities for pre-clinical research and GMP cell therapy production.
Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...
Tevogen Bio Holdings Inc. announced that CD8 Technology Services LLC has signed a letter of intent to design a facility that will support Tevogen’s cell therapy manufacturing efforts. CEO Ryan Saadi ...
In a recent study published in Nature Methods, researchers developed "scAtlasVAE," a deep-learning model to integrate large-scale single-cell ribonucleic acid (RNA) sequencing (scRNA-seq) data, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback